In DISRUPT PAD III, we included the complex, torturous, calcified lesions and risky patients that other studies avoid. Review the results for yourself and see what superior looks like.
Welcome to The Catalyst
Change isn't quick. Unless it's when you experience Intravascular Lithotripsy (IVL) for the first time. Stay apprised of our latest news and insights while discovering how a simple and intuitive tool can be The Catalyst to change the way you think about calcium modification.
In DISRUPT PAD III, we included the complex, torturous, calcified lesions and risky patients that other studies avoid. Review the results for yourself and see what superior looks like.
Topics: Peripheral IVL, Peripheral Clinical Data
Perspective on IVL-Induced Ventricular Capture from Keith D. Dawkins, M.D., Chief Medical Officer, Shockwave Medical, Inc.:
Topics: Coronary IVL, Coronary Clinical Data
Following its presentation as a late-breaking clinical at TCT Connect and simultaneous publication in the Journal of the American College of Cardiology (JACC) we sat down with Dr. Jonathan Hill, Consultant Cardiologist at the Royal Brompton Hospital in London, to get his perspective on the results, how they build on CAD I & II outcomes, and where they fit into clinician’s daily decision-making process when treating calcified lesions. We hope you enjoy his perspective.
Topics: Coronary IVL, Coronary Clinical Data, Shockwave C2, Coronary Conferences
Last month the DISRUPT CAD III investigators, led by co-PIs Drs. Dean Kereiakes and Jonathan Hill, published in the American Heart Journal the trial design and rationale paper titled, “Evaluation of safety and efficacy of coronary intravascular lithotripsy for treatment of severely calcified coronary stenoses: Design and rationale for the Disrupt CAD III trial.”
Topics: Coronary IVL, Coronary Clinical Data
The COVID-19 pandemic has brought a significant focus on important clinical and economic factors such as hospital length-of-stay and hospital resource utilization. Hospitals have been forced to innovate in order to maximize the availability of these resources while treating critical patients.
Topics: Peripheral IVL, Peripheral Clinical Data
No one likes to be stuck between a rock and hard place…well, in interventional cardiology, no one likes to treat a rock in a hard place either! Calcified bifurcations are one of the most complex clinical scenarios faced today on a routine basis. For that reason, we’ve paired up a few international “rockstar” physicians to give you the 101 on calcified bifurcations whether you’re 1,1,1 1,0,1 or 0,1,0…
Topics: Coronary IVL
Prof. Carlo Di Mario, Director of Structural Interventional Cardiology at the Careggi University Hospital in Florence, Italy, and other cardiologists in Florence recently published their initial real-world experience when using intravascular imaging while treating coronary lesions with Intravascular Lithotripsy (IVL).
Topics: Coronary IVL, Coronary Clinical Data, Shockwave C2, Treating Different Ca++ Morphologies
If Shockwave IVL had a personality, we’d like to think that we’d be a bit on the eccentric side. A little unconventional and taking a slightly different path than everyone else. After all, you won’t be successful in introducing a new disruptive technology if you’re marching to the same drumbeat as everyone else.
Topics: Shockwave C2, Coronary Conferences, Treating Different Ca++ Morphologies
In case you weren’t able to make it to EuroPCR’s e-Course last week, you missed a great discussion among some of coronary IVL’s most knowledgeable operators about how they’re using the technology in the real-world setting. Lucky for you, we’ve included the sponsored roundtable discussion below featuring Drs. Benjamin Honton (FR), Javier Escaned (ES) and Michael Lee (HK). We hope you enjoy hearing their perspectives from across Europe and Asia.
Topics: Coronary IVL, Coronary Clinical Data, Shockwave C2, Coronary Conferences
Intravascular Lithotripsy (IVL) has been used and studied across all peripheral vessels, with multiple published studies in CFA, SFA, Popliteal and Infrapopliteal arteries.
Topics: Peripheral IVL, Peripheral Clinical Data
But, right now we're in the early phases of the R&D program. In the meantime, don't miss the IVL application that heart teams are embracing already — maintaining transfemoral TAVR access through heavily calcified iliacs by using IVL.
